According to the 2017 European LeukemiaNet (ELN) AML risk stratification, it is entirely determined by common gene mutations such as NPM1, ASXL1, TP53, RUNX1, FLT3-ITD, double mutation of CEBPA, etc. (5). Here, FLT3 is linked to acute myeloid leukemia.